-+ 0.00%
-+ 0.00%
-+ 0.00%

CSPC wins China clinical trial approval for SYH2092 amylin agonist injection

PUBT·08/27/2026 10:19:37
Listen to the news
CSPC wins China clinical trial approval for SYH2092 amylin agonist injection
  • CSPC won China NMPA clearance to start clinical trials of SYH2092, an amylin receptor agonist injection for obesity.
  • Program also targets improved glycemic control in adults with type 2 diabetes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260827-12302442), on August 27, 2026, and is solely responsible for the information contained therein.